Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Intuit Inc. (INTU) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Intuit Inc.Trade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Intuit Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Intuit Inc. trades at $334.34 (market cap $92.03B). The key difference: Intuit Inc. is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Intuit Inc. pays a 1.43% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYINTU
Market Cap
$29.60B$92.03B
Sector
HealthTechnology
52-Week High
$491.22$717.21
52-Week Low
$205.48$255.07
Enterprise Value
$27.56B$90.49B
Dividend Yield
1.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Intuit Inc.

Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.

The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU